ISRCTN51896330已完成不适用
Multicentric clinical trial on the efficacy and safety of ceftriaxone and sulbactam in lower respiratory tract infectio
Venus Remedies Limited (India)0 个研究点目标入组 105 人开始时间: 2006年6月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age =18 years
- •2. Fever =38°C
- •3. Sputum pus cells >25 high power fields (HPF)
- •4. Buccal epithelial cells <10 HPF
排除标准
- •1. Hypersensitivity to ceftriaxone, sulbactam or related drugs
- •2. Children less than 18 years of age
- •3. Septicemic shock, active pulmonary malignancies, renal and hepatic insufficiencies
研究者
相似试验
尚未招募
2 期
ACENT 1Patients with Sickle Cell Disease.Sickle cell disease (SCD) Foetal haemoglobin (HbF) mutated sickle cell haemoglobin (HbS)LBCTR2024015480ovo Nordisk87
已完成
2 期
Research study investigating how well NDec works in people with sickle cell diseaseSickle cell disease2023-508506-22-00Novo Nordisk A/S15
进行中（未招募）
2 期
Research study investigating how well NDec works in people with sickle cell diseaseCTRI/2023/01/049275ovo Nordisk AS
进行中（未招募）
1 期
Research study investigating how well NDec works in people with sickle cell diseaseSickle cell diseaseCTIS2023-508506-22-00ovo Nordisk A/S87
已完成
2 期
The multicenter clinical trial of the efficacy and safety of bezafibrate for mitochondrial fatty acid Beta-oxidation disordersmitochondrial fatty acid Beta-oxidation disordersJPRN-UMIN000012934Shimane University School of Medicine10